NDAINTRAVENOUSSOLUTION
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREVDUO is a fixed-dose intravenous combination of neostigmine methylsulfate (a cholinesterase inhibitor) and glycopyrrolate (an anticholinergic agent) approved in February 2023. It is used to reverse neuromuscular blockade in patients following anesthesia. The combination works by inhibiting acetylcholinesterase to increase acetylcholine levels while glycopyrrolate blocks unwanted muscarinic side effects.
Peak12.5 years to LOE
As a newly approved specialty IV product in the perioperative space, PREVDUO is in peak commercial growth phase with opportunity for field-based and hospital account management roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PREVDUO presents career opportunity in a niche perioperative space with a newly approved product in peak commercial phase. Roles span hospital-based sales, MSL engagement with anesthesiologists, and brand management with 12+ years of patent-protected market exclusivity.
Brand ManagerMedical Science Liaison
Worked on PREVDUO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.